UNSPSC 51322503: Implitapide

This classification denotes an anti-lipidemic agent with the molecular formula C35H37N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q70OH404HR, chemically known as (alphas)-alpha-(alpha-(2,4-dimethyl-9h-pyrido(2,3-b)indol-9-yl)-p-tolyl)-n-((alphar)-alpha-(hydroxymethyl)benzyl)cyclopentaneacetamide. but generally known as implitapide, which bears US NIH Compound Identifier 5745206. The term IMPLITAPIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 3, 2000, List 44).

UNSPSC 51322503 Implitapide is a Commodity code that represents pharmaceutical products used by state and local healthcare agencies, particularly emergency medical services and public health systems. State and local governments procure this medication and related advanced life support pharmaceuticals through competitive sealed bids and cooperative purchasing agreements. The issuing bodies span city fire and rescue departments, state health agencies, and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions. Recent solicitations show demand for both individual medication line items (specific vial counts and dosages) and comprehensive pharmaceutical catalogs distributed through authorized wholesale channels.

Activity under the code concentrates in Florida and Minnesota, with emerging engagement from Texas health agencies. The City of Tampa's Fire Rescue Department issued an IFB (Bid No. 26P00188) on April 24, 2026, for Advanced Life Support Medications including Labetalol, Epinephrine, Adenosine, and Diltiazem with a response deadline of April 8, 2026 and an estimated contract value of $40,000; the award included a Small Local Business Enterprise sheltered market designation with a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP for Generic Multi Source Pharmaceuticals and OTC Products (Solicitation S1070000015802) with proposals due March 26, 2026, requiring manufacturers to supply through three designated wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) with contracts effective July 1, 2026. The Texas Health and Human Services Commission issued an RFI (HHS0017013) in April 2026 to gather vendor capabilities for a Direct-to-Manufacturer Prescriptions program, signaling potential future demand outside traditional pharmacy benefit manager and wholesaler channels.